Holen Sie sich die Stockscreener-App
9.56
1.16%
0.11
Handel nachbörslich:
9.56
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes $613,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics expands stock incentive plan - Investing.com
Astria Therapeutics Expands Stock Incentive Plan - TipRanks
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Consensus PT from Brokerages - MarketBeat
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year? - MSN
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Grows By 8.6% - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Has $3.46 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria’s OX40 antagonist gains US IND clearance for atopic dermatitis - BioWorld Online
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE - Business Wire
FDA clears Astria Therapeutics' new AD drug for trial By Investing.com - Investing.com Canada
Astria's Navenibart Shows Remarkable 95% HAE Attack Reduction in Phase 1b/2 Trial Results - StockTitan
Astria Therapeutics, Inc. Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Marketscreener.com
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis - Business Wire
Astria Therapeutics' Novel Atopic Dermatitis Drug STAR-0310 Gets FDA Green Light for Clinical Trials - StockTitan
(ATXS) Long Term Investment Analysis - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by Fmr LLC - Defense World
Fmr LLC Buys 1,767,714 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Intech Investment Management LLC Makes New $228,000 Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Redmile Group LLC Takes $3.42 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
RA Capital Management L.P. Has $56.21 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Walleye Capital LLC Has $1.92 Million Stock Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Exciting Opportunities at Astria! New Moves Signal Growth! - Jomfruland.net
Vestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Trend Tracker for (ATXS) - Stock Traders Daily
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema - Seeking Alpha
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60 - MarketBeat
Astria Therapeutics Reports Q3 2024 Financial Results - MSN
Equities Analysts Offer Predictions for ATXS FY2024 Earnings - MarketBeat
Astria Therapeutics’ (ATXS) Buy Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3%What's Next? - MarketBeat
RA Capital Management, L.P. Expands Stake in Astria Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Astria Therapeutics Inc - GuruFocus.com
Oppenheimer Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up on Analyst Upgrade - MarketBeat
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Simply Wall St
Astria's HAE Drug Shows 96% Attack Reduction; Phase 3 Set for Q1 2025 | ATXS Stock News - StockTitan
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - sharewise
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Yahoo Finance
FMR LLC Acquires Significant Stake in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Objective long/short (ATXS) Report - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8%Here's What Happened - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):